Company Profile
NewAmsterdam Pharma Stock Price, News & Analysis
Company overview
Business overview
NewAmsterdam Pharma is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, NewAmsterdam Pharma is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
NewAmsterdam Pharma follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, NewAmsterdam Pharma sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
NAMS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
NewAmsterdam Pharma's catalysts are obicetrapib and the next LDL-lowering clinical and regulatory steps that determine whether the CETP story can stay on track. The stock will move most if the company keeps showing that the program is still credible enough to support a larger cardiovascular franchise.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
Source: NewAmsterdam Pharma
- 02
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
Source: NewAmsterdam Pharma
- 03
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
Source: NewAmsterdam Pharma
- 04
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
Source: NewAmsterdam Pharma
- 05
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
Source: NewAmsterdam Pharma
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.